智通财经APP获悉，科济药业-B(02171)跌超5%，截至发稿，跌5.69%，报12.26港元，成交额6894.05万港元。
消息面上，科济药业近日公布2024年业绩，收益约为人民币3940万元，毛利1474.7万元。净亏损约7.98亿元，同比扩大6.73%；经调整净亏损约7.89亿元，同比增长7.64%；每股基本及摊薄亏损1.44元。据悉，收益主要来自CAR-T细胞疗法泽沃基奥仑赛注射液（商品名：赛恺泽）。这是科济药业在2024年3月向市场推出的首款获批产品，首发价格为115万元/针。赛恺泽的独家商业化权益已经授权给华东医药。
此外，经调整净亏损增长主要是由于研发开支减少；其他亏损净额增加；毛利上升；以股份为基础的薪酬减少。科济药业指出，公司在2024年底进行管线战略调整，更加侧重于通用型CAR-T细胞产品未来的布局，对于若干非流动资产的可回收性具有高度不确定性。因此，科济药业于2024年底对相关非流动资产进行减值测试。按使用价值法计算，已确认该等资产账面值的减值亏损总额为1.89亿元。值得注意的是，科济药业此前遭剔除港股通名单。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.